

# Do adverse respiratory effects of beta<sub>2</sub>-agonists contribute to asthma morbidity and mortality?

In this article, Colin Deeney discusses some controversial issues that have been raised with regards to the regular use of beta<sub>2</sub>-agonist bronchodilators in the treatment of asthma. (This article appeared in PJ, 12 August 2006, pp193-5)

Short-acting beta<sub>2</sub>-agonists (SABAs) have been used as first line therapy for the acute relief of bronchoconstriction in asthma for several decades. However, anti-inflammatory therapies are now considered the cornerstone of chronic asthma management.<sup>1,2</sup> Therefore, it is now recommended that unless individual patients are shown to benefit from regular treatment SABAs are used only when required for acute symptoms. Indeed, regular use is usually seen as an indication of poor asthma control and a need for preventive medication. In contrast, long-acting beta<sub>2</sub>-agonists (LABAs) are recommended for regular use to control persistent breakthrough symptoms. They are only recommended as an adjunct to preventive inhaled corticosteroids and not as monotherapy.

These recommendations, however, fall against a background of concern expressed about the possibility of increased morbidity and mortality with the regular use of beta<sub>2</sub>-agonists since at least the mid-1960s. Their use first became a concern after a study in England and Wales showed a rise in deaths that occurred with the introduction of isoprenaline. Then, in New Zealand during the 1970s, again a rise in deaths corresponded with an increase in the use of the fenoterol. In both these cases the cause of the increased mortality was attributed to cardiovascular adverse effects, because isoprenaline is a non-selective agonist and fenoterol is a fairly non-selective beta<sub>2</sub>-agonist. However, a subsequent study<sup>3</sup> raised the suggestion that the increasing use of beta<sub>2</sub>-agonists per se may actually be contributing to the world-wide increase in morbidity and mortality from asthma.<sup>3</sup>

Concern regarding potential adverse respiratory effects has focused chiefly on tolerance to the effects of the drugs and also the possibility of rebound airway hyper-responsiveness, increased inflammation or the masking of the underlying disease. Most of the evidence, and thus concern has related to SABAs rather than LABAs. Indeed previous reviews and thus guidelines<sup>1,2,4</sup> have found

concern regarding the regular use of LABAs unjustified. However, a recent meta-analysis concluded that regular use of not only SABAs but also LABAs has adverse effects on respiratory function.<sup>5</sup> The review suggested that use of all beta<sub>2</sub>-agonists may be associated with poorer disease control in patients with asthma compared with no use at all.<sup>5</sup> Furthermore, an interim analysis of another recent study found a higher number of asthma-related deaths or life-threatening events among patients treated with salmeterol compared with placebo.<sup>6</sup>

This was then followed by the results of another study that found a numerical but not statistically significant greater incidence of asthma-related deaths in patients with asthma treated with salmeterol compared with regular salbutamol.<sup>7</sup> Indeed in the US, the Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee has recently requested that products containing either salmeterol or formoterol should have a "black box" warning of the risk of asthma exacerbations and the possibility of an increased risk of respiratory-related deaths. Yet this contrasts with the findings of another recent large population based study<sup>8</sup> that found that SABAs, but not LABAs, were associated with a small but significant increase in mortality. The authors suggested this increase in mortality had several explanations only one of which may be a direct adverse effect. Therefore the suggestion that beta<sub>2</sub>-agonists may be contributing to an increase in morbidity and mortality from asthma is controversial.

There are of course pharmacological and physicochemical differences between SABAs and LABAs. Formoterol is a full agonist and is thought to owe the long duration of action to moderate lipophilicity causing it to be retained in the lipid cell membrane and released slowly.<sup>9</sup> Salmeterol is a partial agonist that binds almost irreversibly with the beta<sub>2</sub>-adrenoceptor.<sup>10</sup> Its long duration of action may also be due to its lipophilicity resulting in a slow onset but prolonged receptor activation.<sup>9</sup> Alternatively, it has been suggested that salmeterol's duration of activity may be due to the fact that it binds not only to the active site of the receptor but also to another site — the "exosite". This anchors it to the receptor and provides for repetitive active-site binding events.<sup>11</sup> However, the relevance of these differences in relation to adverse effects

is uncertain. The question therefore still arises: are the adverse respiratory effects associated with SABAs also associated with formoterol and salmeterol?

## Tolerance

Studies have shown that regular use of both SABAs and LABAs leads to tolerance to both peak effect and duration of bronchodilation with subsequent doses.<sup>12-15</sup> In addition, there is evidence that tolerance develops to the use of SABAs following regular use of LABAs. However, other studies have found tolerance to LABAs to be of little clinical significance.<sup>16-22</sup> It has been suggested that this is because these studies only involved patients with mild to moderate asthma who were not actually experiencing bronchospasm during investigation.<sup>23</sup> This suggestion followed two studies that found tolerance to SABAs in patients actually experiencing bronchospasm following regular terbutaline<sup>24</sup> and formoterol,<sup>25</sup> the latter despite regular inhaled corticosteroids. Therefore, there is concern regarding tolerance to beta<sub>2</sub>-agonist bronchoprotective properties, ie, the ability to prevent bronchospasm induced by bronchoconstrictor stimuli. This may be a concern should the patient have an acute attack. Indeed, several studies have shown that regular use of SABAs leads to loss of bronchoprotection to artificial and natural stimuli such as methacholine,<sup>3,15,24-27</sup> histamine,<sup>28,29</sup> adenosine 5'-monophosphate (AMP),<sup>15</sup> propranolol,<sup>28</sup> allergens<sup>26,30</sup> and exercise.<sup>31</sup> There is also evidence that regular use of LABAs is associated with loss of bronchoprotection against methacholine,<sup>32-40</sup> allergen challenge<sup>41</sup> and exercise.<sup>42-44</sup> Furthermore, this tolerance has been shown not to be preventable by inhaled corticosteroids.<sup>36,37,43</sup>

It is thought that tolerance to the bronchodilatory and bronchoprotective effects of beta<sub>2</sub>-agonists is associated with reductions in both the density of peripheral beta<sub>2</sub>-adrenoceptors (down-regulation) and the binding affinity of the receptors (desensitisation).<sup>45</sup> As regards tolerance to bronchoprotective effects, bronchoconstrictive stimuli can act either directly on smooth muscles or indirectly by stimulating the release of mediators from mast cells. Tolerance could, therefore, theoretically be due to a down-regulation of beta<sub>2</sub>-receptors on either

**Colin Deeney**, MRPharmS, is a community pharmacist in Ireland with an interest in asthma, concomitant hyperventilation and the Buteyko Institute Method of breathing (e-mail colindeeney@iol.ie)

airway smooth muscle or mast cells, or both.

It appears that with SABAs, tolerance to the bronchoprotective effects against bronchoconstriction induced by AMP is of a greater magnitude than tolerance to the bronchoprotective against direct stimulation by methacholine.<sup>25</sup> Since AMP produces bronchoconstriction through the release of mediators from mast cells and methacholine directly constricts airway smooth muscle, this differential has been interpreted as selective beta<sub>2</sub>-adrenoceptor refractoriness at the mucosal mast cellular level.<sup>25</sup>

With LABAs the situation is somewhat different. There is tolerance to both the bronchoprotective effects against methacholine<sup>23</sup> and AMP<sup>46</sup> with formoterol. However, in contrast to both formoterol and SABAs, regular salmeterol treatment has been shown to lead to loss of bronchoprotection to direct stimulation by methacholine but not to AMP.<sup>47</sup> This implies that mast cell beta<sub>2</sub>-adrenoceptor downregulation is not the mechanism for tolerance to the bronchoprotection with regular salmeterol therapy. However other studies<sup>42-44</sup> have found a loss of salmeterol bronchoprotection to the exercise, which is also considered an indirect cause of bronchoconstriction. Although this may be attributable to a difference in the mechanisms of bronchoconstriction between AMP and exercise, it also adds to a lack of clarity. Furthermore, in mild asthma, single doses of salmeterol do not appear to protect more against AMP than against methacholine challenge.<sup>38</sup> Therefore, at present it is impossible to conclude that loss of bronchoprotection by salmeterol is due to an entirely different reason than SABAs.

## Polymorphism

In recent years attention has been drawn to beta<sub>2</sub>-adrenoceptor polymorphism. For example, the Glu-27 variant is completely resistant to agonist-promoted down-regulation compared with the Gln-27 variant<sup>48,49</sup> and is associated with lower bronchial hyper-reactivity.<sup>50</sup> There is also an association between elevated levels of IgE and the Gln-27 variant.<sup>51</sup> *In vitro* studies have also shown that, compared with the Arg-16 form, the Gly-16 variant of the beta<sub>2</sub>-adrenoceptor is more down-regulated by beta<sub>2</sub>-agonist exposure. Indeed the Gly-16 variant has been associated with nocturnal asthma<sup>52</sup> and an increased requirement for oral corticosteroids.<sup>53</sup> However in one study, it was patients with the Arg-16 variant who experienced a decline in morning peak flow with regular beta<sub>2</sub>-agonist use.<sup>54</sup> The sharpest decreases occurred in the four-week period after beta<sub>2</sub>-agonists had been discontinued. Patients with this Arg-16 variant who were in the "as required" group experienced no adverse effects. Patients with the Gly-16 variant did not experience such an effect. Furthermore, in another study, subjects of all genotypes demonstrated poorer control of asthma when treated with regular fenoterol compared with "as required" therapy.<sup>55</sup> However, those patients with the Gly-

16 variant did not have the increase in bronchial responsiveness experienced with the other genotypes. So although beta<sub>2</sub>-adrenoceptor polymorphisms may alter the response to the use of beta<sub>2</sub>-agonists the clinical effects and associations noted have been contradictory and warrant further study.

## Rebound airway hyper-responsiveness

It has also been suggested that regular use of beta<sub>2</sub>-agonists may actually enhance bronchial contractile sensitivity, referred to as rebound bronchial hyper-responsiveness or hyper-reactivity. In other words, there is an increase in bronchoconstrictive response upon challenge with regular use of the drugs. The hyper-responsiveness appears to be transient and occurs after the bronchodilator effect of the beta<sub>2</sub>-agonist has waned. Given the fact that beta<sub>2</sub>-agonists are used to alleviate bronchoconstriction, this could result in a cycle of increased bronchoconstriction upon challenge followed by increased use of the bronchodilator and again increased hyper-responsiveness. Put more crudely, the more often a beta<sub>2</sub>-agonist is used the more it may appear to the user that it is needed. Again, although there is some evidence of this occurring with LABAs,<sup>32,56</sup> there is more evidence of it occurring with SABAs.<sup>28-30,57</sup> One possible mechanism for this increased sensitivity is cross talk between bronchodilating and bronchoprotective pathways (the G protein-coupled receptor pathway). This could then lead to enhanced signalling. This has been found in a study in mice,<sup>58</sup> with the researchers suggesting that it may be due to an adaptive programme that promotes a defined equilibrium so as to maintain bronchomotor tone or reactivity within a specific range.

Research has also suggested that chirality may be relevant. It appears that bronchodilation is almost exclusively the result of stimulation by the R-enantiomer, with the S-enantiomer making little therapeutic contribution (salbutamol and formoterol have been studied). In contrast the S-enantiomer of the racemic beta<sub>2</sub>-agonist appears to be responsible for rebound bronchial hyper-responsiveness.<sup>59-61</sup> Furthermore, studies with salbutamol have also found that the racemate undergoes stereoselective sulphatation by sulfotransferases mainly in the gut and liver, so that unwanted S-enantiomer remains for a longer time in the body and reaches higher plasma levels than R-enantiomer.<sup>62,63</sup> Therefore, the use of the R-enantiomer alone may reduce the likelihood of pulmonary adverse effects while maintaining clinical efficacy.

## Increased Inflammation

Bronchoalveolar lavages, sputum samples and biopsies after regular treatment with SABAs have shown an increase in a number of inflammatory indicators, as found in both the early and late asthmatic response. For example, after as little as 10 days there is an increase in allergen-induced late asthmatic response indicators such as mast cell tryptase,<sup>64</sup>

eosinophils,<sup>64-68</sup> sputum eosinophilic cationic protein<sup>66</sup> and chemokine (CXCL8/interleukin-8) production.<sup>69</sup> The situation regarding LABAs is again somewhat more complicated. A number of *in vitro* and *in vivo* studies have suggested that LABAs may actually have an anti-inflammatory effect.<sup>17,70-72</sup> However, although others have failed to show any anti- or pro-inflammatory effect,<sup>73-76</sup> one study found that there was an increase in markers of inflammation with salmeterol.<sup>77</sup> This increase was reduced with triamcinolone.<sup>77</sup>

It has been suggested that there is an additional benefit in using this combination of a LABA along with inhaled corticosteroids rather than either of the two drugs separately. For example, a number of clinical studies have shown that addition of a LABA to an inhaled corticosteroid gives a better outcome than increasing the dose of the corticosteroids in terms of a number of end points, including exacerbation rate.<sup>17,75,78,79</sup> In addition, an *in vitro* study has shown that beta<sub>2</sub>-adrenoceptor down-regulation can be reversed by exposure to corticosteroids.<sup>80</sup> Other *in vitro* studies have shown that combining a LABA and corticosteroid, when compared with either agent alone, reduces cytokine release from inflammatory cells,<sup>81</sup> inhibits the release of cytokine-induced intercellular adhesion molecule-1 (ICAM-1)<sup>79</sup> and inhibits vascular cell adhesion molecule-1 (VCAM-1) upregulation.<sup>79</sup> The combination also inhibits granulocyte-macrophage colony stimulating factor (GM-CSF) production of human fibroblasts which should in turn inhibit the migration of inflammatory cells into pulmonary tissue of asthmatic airways.<sup>79</sup> Indeed, another study<sup>82</sup> has attributed this anti-inflammatory effect of the combination to the R-enantiomer, again with the S-enantiomer having a deleterious effect by reversing this. This study found similar results for both salbutamol and formoterol.

## Effects of chronic bronchodilation

It has also been suggested that regular use of LABAs may mask the underlying disease and delay awareness of worsening asthma and airway inflammation. For example, the prolonged bronchodilator effect of LABAs could make such clinical markers as symptom scores, nocturnal awakenings, lung function tests and beta<sub>2</sub>-agonist reliever use less useful in detecting worsening inflammation. Studies have shown that the effects of even a single dose of LABAs can mask the clinical effects of airway inflammatory-cell influx following challenge.<sup>83-85</sup> It has also been found that the frequency of emergency events is greater during treatment with LABAs than with no bronchodilator at all, despite concomitant use of inhaled corticosteroids.<sup>86</sup> This suggests the possibility that LABAs may mask a major exacerbation and delay intervention.

Another suggestion has been that chronic bronchodilation could lead to an increased load. That is, lead to an excessive allergen, microbe or irritant deposition from the atmos-

phere and as a result increase, for example, acute inflammation or bronchial hyperactivity.<sup>87</sup> However, there is little evidence to support or negate this possibility.

### Hyperventilation and hypocapnia

One pharmacologically predictable, yet rarely mentioned, effect of beta-adrenoceptor stimulation is increased ventilation, ie, an increase in both the rate and volume of breathing measured as the minute volume. Perhaps it has not been considered of clinical significance. However, recently there has been an increased awareness of the fact that there is dysfunctional breathing including hyperventilation associated with asthma.<sup>88</sup> Patients with asthma hyperventilate during an asthma attack.<sup>89,90</sup> Furthermore, hyperventilation makes asthma worse. For example, acute voluntary hyperventilation causes bronchoconstriction in people with asthma.<sup>91</sup> Hyperventilation reduces arterial carbon dioxide (PaCO<sub>2</sub>) levels leading to below normal levels known as hypocapnia. Indeed people with asthma have been found to have hypocapnia even when their symptoms are mild.<sup>92,93</sup> Hypocapnia is known to cause and potentiate bronchoconstriction<sup>94-96</sup> and is associated with rebound bronchial hyper-responsiveness.<sup>95</sup> Carbon dioxide levels can drop particularly low at the time of an asthma attack.<sup>96,97</sup> Therefore it has been hypothesised that hypocapnia contributes to,<sup>92,95,98,99</sup> or indeed may actually cause (see [www.buteyko.info](http://www.buteyko.info)), airway obstruction and bronchospasm in asthma. Furthermore, hypocapnia has been shown to attenuate hypoxic pulmonary vasoconstriction, worsen intrapulmonary shunt and systemic oxygenation in dogs.<sup>100</sup> Therefore, one adverse effect of both SABAs and LABAs could be to exacerbate asthma by increasing ventilation causing or exacerbating hyperventilation and hypocapnia. Indeed hypocapnia is a known effect of beta<sub>2</sub>-agonists.<sup>101</sup>

### Conclusion

As I stated in the introduction, previous reviews and guidelines<sup>1,2,4</sup> have found concern regarding the regular use of beta<sub>2</sub>-agonists, and LABAs, in particular, unjustified. However, the results of one recent meta-analysis<sup>3</sup> found that most of the studies in the past that have concluded that beta<sub>2</sub>-agonists are beneficial were actually funded or sponsored by pharmaceutical companies that might have had a conflict of interest. In other words, they stand to gain financially from beta<sub>2</sub>-agonist use. Most of the studies not funded or sponsored by pharmaceutical companies found no benefit. This is a controversial statement. Perhaps more importantly, the authors also pointed out that "to date no randomised trials have demonstrated a reduction in disease progression or in mortality with the use of beta<sub>2</sub>-agonists". This concurs with the opinion of others that "bronchodilator drugs improve lung function in the short term, but their effects are limited to the duration of action of the drug within the airway. Cessation of treatment leads to a rapid decline in lung

function, indicating that these protective effects are due to functional antagonism of bronchoconstriction and are not related to any fundamental effect on airway structure."<sup>102</sup> In other words, although beta<sub>2</sub>-agonists and LABAs, in particular, control symptoms, their use is of limited value in terms of chronic disease outcomes.

In conclusion, although this article is hardly the last word on potential respiratory adverse effects with beta<sub>2</sub>-agonists, it summarises some of the concerns that have been raised. Indeed, there appears to be sufficient evidence to advise the use of SABAs on an as-needed basis only, as current guidelines recommend. As regards LABAs, there is some evidence that they may augment inhaled corticosteroids in the control and management of asthma, as is recommended in current guidelines. However, there is still some concern with their use. There is some evidence of tolerance to their bronchodilator and bronchoprotective effects. There is also tolerance to SABAs after the use of LABAs. Concern has also been expressed that, by artificially maintaining bronchodilation for a long period, LABAs could mask the underlying disease progress and increase load. Therefore beta<sub>2</sub>-agonists should continue to be used with caution.

### References

1. The British Thoracic Society/Scottish Intercollegiate Guidelines Network. British Guidelines on the Management of Asthma. *Thorax* 2003;58(Suppl 1):i17-i18.
2. The Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. NIH Publication No 02-3659 Issued January, 1995 (updated 2004). Available at [www.ginasthma.org](http://www.ginasthma.org) (accessed 21 July 2006).
3. Sears MR, Taylor DR, Print CG, Lake DC, Li QQ, Flannery EM, et al. Regular inhaled beta-agonist treatment in bronchial asthma. *Lancet* 1990;336:1391-6.
4. Walters EH, Walters JAE, Gibson MDP. Long-acting beta agonists for stable chronic asthma. The Cochrane Database of Systematic Reviews 2003, Issue 3.
5. Salpeter SR, Ormiston TM, Salpeter EE. Meta-analysis: respiratory tolerance to regular beta<sub>2</sub>-agonist use in patients with asthma. *Annals of Internal Medicine* 2004;140:802-13.
6. US Food and Drug Administration. Medical officer review. Provided for: Meeting of Pulmonary-Allergy Drugs Advisory Committee, July 13, 2005. Available at: [www.fda.gov/ohrtms/dockets/ac/05/briefing/2005-4148B1\\_03\\_02-FDA-Smart-Study.pdf](http://www.fda.gov/ohrtms/dockets/ac/05/briefing/2005-4148B1_03_02-FDA-Smart-Study.pdf) (accessed 23 February 2006).
7. Castle W, Fuller R, Hall J, Palmer J. Seven nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. *BMJ* 1993;306:1034-7.
8. Anderson HR, Ayres JG, Sturdy PM, Bland JM, Butland BK, Peckitt C et al. Bronchodilator treatment and deaths from asthma: case-control study. *BMJ* 2005;330:117.
9. Anderson GP, Linden A, Rabe KF. Why are long-acting beta<sub>2</sub>-agonists long-acting? *European Respiratory Journal* 1994;7:569-78.
10. Roux FJ, Grandordy B, Douglas JS. Functional and binding characteristics of long acting beta<sub>2</sub>-agonists in lung and heart. *American Journal of Respiratory and Critical Care Medicine* 1996;153:1489-95.
11. Green SA, Spasoff AP, Coleman RA, Johnson M, Liggett SB. Sustained activation of a G protein-coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor. *Journal of Biological Chemistry* 1996;271:24029-35.
12. Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. *Lancet* 1995;346:201-6.
13. Newnham DM, Grove A, McDewitt DG, Lipworth BJ. Subsensitivity of bronchodilator and systemic beta<sub>2</sub>-adrenoceptor responses after regular twice daily treatment with formoterol dry powder in asthmatic patients. *Thorax* 1995;50:497-504.
14. Tan KS, Grove A, McLean A, Grosspelius Y, Hall IP, Lipworth BJ. Systemic corticosteroid rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. *American Journal of Respiratory and Critical Care Medicine* 1997;156:28-35.
15. Yates DH, Sussman HS, Shaw MJ, Barnes PJ, Chung KF. Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment. *American Journal of Respiratory and Critical Care Medicine* 1995;152:1170-4.
16. van Noord JA, Schreurs AIM, Mol SJM, Mulder PGH. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. *Thorax* 1999;54:207-12.
17. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. *New England Journal of Medicine* 1997;337:1405-11.
18. Grove A, Lipworth BJ. Effects of prior treatment with salmeterol and formoterol on airway and systemic beta<sub>2</sub>-responses to fenoterol. *Thorax* 1996;51:585-9.
19. Arledge TE, Liddle R, Stahl E, Rossing TH. Salmeterol does not cause tolerance during long-term asthma therapy. *Journal of Allergy and Clinical Immunology* 1996;98:1116-9.
20. Langley SJ, Masterson CM, Batty EP, Woodcock A. Bronchodilator response to salbutamol after chronic dosing with salmeterol or placebo. *European Respiratory Journal* 1998;11:1081-5.
21. Azizi I, Hall IP, McFarlane LC, Lipworth BJ. Beta<sub>2</sub>-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma. *Journal of Allergy and Clinical Immunology* 1998;101:337-41.
22. Nelson HS, Berkowitz RB, Tinkelman DA, Emmett AH, Rickard KA, Yancey SW. Lack of subsensitivity to salbutamol after treatment with salmeterol in patients with asthma. *American Journal of Respiratory and Critical Care Medicine* 1999;159:1556-61.
23. Jones SL, Cowan JO, Flannery EM, Hancox RJ, Herbison GP, Taylor DR. Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol. *European Respiratory Journal* 2001;17:368-73.
24. Hancox RJ, Aldridge RE, Cowan JO, Flannery EM, Herbison GP, McLachlan CR, et al. Tolerance to beta-agonists during acute bronchoconstriction. *European Respiratory Journal* 1999;14:283-7.
25. O'Connor BJ, Aikman SL, Barnes PJ. Tolerance to the nonbronchodilator effects of inhaled beta<sub>2</sub>-agonists in asthma. *New England Journal of Medicine* 1992;327:1204-208.
26. Bhagat R, Swystun VA, Cockcroft DW. Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine: dose response. *Journal of Allergy and Clinical Immunology* 1996;97:47-52.
27. Drazen JM, Israel E, Boushey HA, Chinchilli VM, Fahy JV, Fish JE, et al. The National Heart Lung and Blood Institute's Asthma Clinical Research Network. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. *New England Journal of Medicine* 1996;335:841-7.
28. Kraan J, Koëter GH, vd Mark TW, Slieter HJ, de Vries K. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. *Journal of Allergy and Clinical Immunology* 1985;76:628-36.
29. Valthänen AS, Higgins BG, Knox AJ, Britton JR, Tattersfield AE. Rebound increase in bronchial responsiveness after

- treatment with inhaled terbutaline. *Lancet* 1988;12:554-8.
30. Cockcroft DW, McParland CP, Britto SA, Swystun VA, Rutherford BA. Regular inhaled salbutamol and airways responsiveness to allergen. *Lancet* 1993;342:833-7.
  31. Hancox RJ, Subbarao P, Kamada D, Watson RM, Hargreave FE, Inman MD. Beta<sub>2</sub>-agonist tolerance and exercise-induced bronchospasm. *American Journal of Respiratory and Critical Care Medicine* 2002;165:1068-70.
  32. Cheung D, Timmers MC, Zwinderman AH, Bel EH, Dijkman JH, Sterk PJ. Long-term effects of a long-acting beta<sub>2</sub>-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. *New England Journal of Medicine* 1992;327:1198-203.
  33. Bhagat R, Kalra S, Swystun VA, Cockcroft DW. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. *Chest* 1995;108:1235-9.
  34. Lipworth B, Tan S, Devlin M, Aiken T, Baker R, Hendrick D. Effects of treatment with formoterol on bronchoprotection against methacholine. *American Journal of Medicine* 1998;104:431-8.
  35. Booth H, Bish R, Walters J, Whitehead F, Walters EH. Salmeterol tachyphylaxis in steroid treated asthmatic subjects. *Thorax* 1996;51:1100-4.
  36. Yates DH, Kharitonov SA, Barnes PJ. An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled 2-agonist. *American Journal of Respiratory and Critical Care Medicine* 1996;154:1603-7.
  37. Kalra S, Swystun VA, Bhagat R, Cockcroft DW. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. *Chest* 1996;109:953-6.
  38. Yates DH, Worsdell M, Barnes PJ. Effect of regular salmeterol treatment on albuterol-induced bronchoprotection in mild asthma. *American Journal of Respiratory and Critical Care Medicine* 1997;156:988-91.
  39. Drobar DE, Davis EE, Cockcroft DW. Tolerance to the bronchoprotective effect of salmeterol 12 after starting twice daily treatment. *Annals of Allergy Asthma and Immunology* 1998;80:31-34.
  40. van der Woude HJ, Winter TH, Aalbers R. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta<sub>2</sub>-agonists. *Thorax* 2001;56:529-35.
  41. Giannini D, Carletti A, Dente FL, Bacci E, Franci AD, Vagaggini B, et al. Tolerance to the protective effect of salmeterol on allergen challenge. *Chest* 1996;110:1452-7.
  42. Ramage L, Lipworth BJ, Ingram CG, Cree IA, Dhillon DP. Reduced protection against exercise-induced bronchoconstriction after chronic dosing with salmeterol. *Respiratory Medicine* 1994;88:363-8.
  43. Simons FER, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effects of Salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. *Pediatrics* 1997;99:655-8.
  44. Kemp JP, Dockhorn RJ, Busse WW, Bleeker ER, Van ASA. Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm. *American Journal of Respiratory and Critical Care Medicine* 1994;150:1612-5.
  45. Johnson M. The beta-adrenoceptor. *American Journal of Respiratory and Critical Care Medicine* 1998;158:S146-S153.
  46. Aziz I, Tan KS, Hall IP, Devlin MM, Lipworth BJ. Subsensitization to bronchoprotection against adenosine monophosphate challenge following regular once-daily formoterol. *European Respiratory Journal* 1998;12:580-4.
  47. Soler M, Joos L, Bolliger CI, Elsasser S, Perruchoud AP. Bronchoprotection by salmeterol: cell stabilization or functional antagonism? Comparative effects on histamine and AMP-induced bronchoconstriction. *European Respiratory Journal* 1994;7:1973-7.
  48. Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. *Biochemistry* 1994;33:9414-9.
  49. Green SA, Turki J, Bejarano P, Hall IP, Liggett SB. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. *American Journal of Respiratory Cell and Molecular Biology* 1995;13:25-33.
  50. Hall IP, Wheatley A, Wilding P, Liggett SB. Association of Glu 27 beta 2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. *Lancet* 1995;345:1213-4.
  51. Dewar JC, Wilkinson J, Wheatley A, Thomas NS, Doull I, Morton N et al. The glutamine 27 beta 2-adrenoceptor polymorphism is associated with elevated IgE levels in asthmatic families. *Journal of Allergy and Clinical Immunology* 1997;100:261-5.
  52. Turki J, Pak J, Green SA, Martin RJ, Liggett SB. Polymorphisms of the beta 2-adrenergic receptor in nocturnal and non-nocturnal asthma: evidence that Gly16 correlates with the nocturnal phenotype. *Journal of Clinical Investigation* 1995;95:1635-41.
  53. Reihnsaus E, Innis M, MacIntyre N, Liggett SB. Mutations in the gene encoding for the beta2-adrenergic receptor in normal and asthmatic subjects. *American Journal of Respiratory Cell and Molecular Biology* 1993;8:334-9.
  54. Israel E, Drazen JM, Liggett SB, Boushey HA, Cherniack RM, Chinchilli VM, et al. The effect of polymorphisms of the beta<sub>2</sub>-adrenergic receptor on the response to regular use of albuterol in asthma. *American Journal of Respiratory and Critical Care Medicine* 2000;162:75-80.
  55. Hancox RJ, Sears MR, Taylor DR. Polymorphism of the beta2-adrenoceptor and the response to long-term beta2-agonist therapy in asthma. *European Respiratory Journal* 1998;11:589-93.
  56. Verbeke AA, Frost C, Roorda RJ, van der Laag H, Kerrebijn KF. One year treatment with salmeterol compared with budesonide in children with asthma. The Dutch Paediatric Asthma Study Group. *American Journal of Respiratory and Critical Care Medicine* 1997;156:685-7.
  57. Van Schayck CP, Graafma SJ, Visch MB, Dompeling E, van Weel C, van Herwaarden CLA. Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol. *Journal of Allergy and Clinical Immunology* 1990;86:793-800.
  58. McGraw DW, Almoosa KF, Paul RJ, Koblick EK, Liggett SB. Antithetic regulation by beta-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway beta-agonist paradox. *Journal of Clinical Investigation* 2003;112:619-26.
  59. Handley D. The asthma-like pharmacology and toxicology of (S)-isomers of beta agonists. *Journal of Allergy and Clinical Immunology* 1999;104:S69-S76.
  60. Nelson HS. Clinical experience with levalbuterol. *Journal of Allergy and Clinical Immunology* 1999;104:S77-S84.
  61. Keir S, Page C, Spina D. Bronchial hyperresponsiveness induced by chronic treatment with albuterol: Role of sensory nerves. *Journal of Allergy and Clinical Immunology* 2002;110:388-94.
  62. Hartman AP, Wilson AA, Wilson HM, Aberg G, Falany CN, Walle T. Enantioselective sulfation of beta2-receptor agonists by the human intestine and the recombinant M-form phenosulfotransferase. *Chirality* 1998;10:800-3.
  63. Walle T, Eaton EA, Walle UK, Pesola GR. Stereoselective metabolism of RS-albuterol in humans. *Clinical Reviews in Allergy & Immunology* 1996;14:101-13.
  64. Swystun VA, Gordon JR, Davis EB, Zhang X, Cockcroft DW. Mast cell tryptase release and asthmatic responses to allergen increase with regular use of salbutamol. *Journal of Allergy and Clinical Immunology* 2000;106:57-64.
  65. Cockcroft DW, O'Byrne PM, Swystun VA, Bhagat R. Regular use of inhaled albuterol on allergen-induced late asthmatic response. *Journal of Allergy and Clinical Immunology* 1995;96:44-49.
  66. Gauvreau GM, Jordana M, Watson RM, Cockcroft DW, O'Byrne PM. Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. *American Journal of Respiratory and Critical Care Medicine* 1997;156:1738-45.
  67. Manditsas DN, Wang J, Devalia JL, Trigg CJ, McAulay AE, Davies RJ. Regular albuterol, nedocromil sodium, and bronchial inflammation in asthma. *American Journal of Respiratory and Critical Care Medicine* 1995;151:1925-30.
  68. Aldridge RE, Hancox RJ, Robin Taylor D, Cowan JO, Winn MC, Frampton CM, et al. Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. *American Journal of Respiratory and Critical Care Medicine* 2000;161:1459-64.
  69. Gordon JR, Swystun VA, Li F, Zhang X, Davis EE, Hull P, et al. Regular salbutamol use increases CXCL8 responses in asthma: relationship to the eosinophil response. *European Respiratory Journal* 2003;22:118-26.
  70. Dente FL, Bancalari L, Bacci E, Bartoli ML, Carnevali S, Cianchetti S, et al. Effect of a single dose of salmeterol on the increase in airway eosinophils induced by allergen challenge in asthmatic subjects. *Thorax* 1999;54:622-4.
  71. Li X, Ward C, Thien F, Bish R, Bamford T, Bao X, et al. An anti-inflammatory effect of salmeterol, a long acting beta2 agonist, assessed in airway biopsies and bronchial lavage in asthma. *American Journal of Respiratory and Critical Care Medicine* 1999;160:1493-9.
  72. Wallin A, Sandstrom T, Soderberg M, Howarth P, Lundback BO, Della-Cioppa G, et al. The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. *American Journal of Respiratory and Critical Care Medicine* 1999;159:79-86.
  73. Gardiner PV, Ward C, Booth H, Allison A, Hendrick DJ, Walters EH. Effect of eight weeks of treatment with salmeterol on bronchodilator lavage inflammatory indices in asthmatics. *American Journal of Respiratory and Critical Care Medicine* 1994;150:1606-11.
  74. Roberts JA, Bradding P, Britten KM, Walls AF, Wilson S, Gratzou C, Holgate ST, Howarth PH. The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. *European Respiratory Journal* 1999;14:275-8.
  75. Tattersfield AE, Postma DS, Barnes PJ, Svensson K, Bauer CA, O'Byrne PM, et al. Exacerbations of asthma, a descriptive study of 425 severe exacerbations. *American Journal of Respiratory and Critical Care Medicine* 1999;160:594-9.
  76. Boulet LP, Turcotte H, Boutet M, Dube J, Gagnon M, Lavolette M. Influence of salmeterol on chronic and allergen-induced airway inflammation in mild allergic asthma — a pilot study. *Current Therapeutic Research — Clinical and Experimental* 1997;58:240-59.
  77. Lazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske RF, Sorkness CA, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma. *JAMA* 2001;285:2583-93.
  78. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). *BMJ* 2000;320:1368-73.
  79. Spoelstra FM, Postma DS, Hovenga H, Noordhoek JA, Kauffman HF. Budesonide and formoterol exert an additive effect on the inhibition of ICAM-1 and VCAM-1 upregulation and GM-CSF production of human lung fibroblasts. *American Journal of Respiratory and Critical Care Medicine* 1999;159:A197.
  80. Hui KK, Conolly ME, Tashkin DP. Reversal of human lymphocyte beta-adrenoceptor desensitization by glucocorticoids. *Clinical Pharmacology and Therapeutics* 1982;32:566-71.
  81. Oddera S, Silvestri M, Testi R, Rossi GA. Salmeterol enhances the inhibitory activity of dexamethasone on allergen-induced blood mononuclear cell activation. *Respiration* 1998;68:199-204.
  82. Ameredes BT, Calhoun WJ. Modulation of GM-CSF release by enantiomers of beta-agonists in human airway smooth muscle. *Journal of Allergy and Clinical Immunology* 2005;116:65-72.
  83. McIvor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on

- airway inflammation in asthma. *American Journal of Respiratory and Critical Care Medicine* 1998;158:924–30.
84. Pizzichini MMM, Kidney JC, Wong BJO, Morris MM, Efthimiadis A, Dolovich J, et al. Effect of salmeterol compared with beclomethasone on allergen-induced asthmatic and inflammatory responses. *European Respiratory Journal* 1996;9:449–55.
85. Wong BJ, Dolovich J, Ramsdale EH, O'Byrne PM, Gontownick L, Denburg JA, et al. Formoterol compared with beclomethasone and placebo on allergen-induced asthmatic responses. *American Review of Respiratory Disease* 1992;146:1156–60.
86. Taylor DR, Town GI, Herbison GP, Boothman-Burrell D, Flannery EM, Hancock B, et al. Asthma control during long term treatment with regular inhaled salbutamol and salmeterol. *Thorax* 1998;53:744–52.
87. Lai CK, Twentyman OP, Holgate ST. The effect of an increase in inhaled allergen dose after rimiterol hydrobromide on the occurrence and magnitude of the late asthmatic response and the associated change in nonspecific bronchial responsiveness. *American Review of Respiratory Disease* 1989;140:917–23.
88. Thomas M, McKinley RK, Freeman E, Foy C, Prodder P, Price D. Breathing retraining for dysfunctional breathing in asthma: a randomised controlled trial. *Thorax* 2003;58:110–5.
89. Johnson BD, Scanlon PD, Beck KC. Regulation of ventilatory capacity during exercise in asthmatics. *Journal of Applied Physiology* 1995;79:892–90.
90. McFadden ER, Lyons HA. Arterial-blood gas tension in asthma. *New England Journal of Medicine* 1968;278:1029–32.
91. Hurwitz KM, Argyros GJ, Roach JM, Eliasson AH, Phillips YY. Interpretation of eucapnic voluntary hyperventilation in the diagnosis of asthma. *Chest* 1995;108:1240–5.
92. Ritz T, Meuret AE, Wilhelm FH, Roth WT. Ambulatory monitoring of spirometric lung function and pCO<sub>2</sub> in asthma. Paper submitted to the Society for Psychophysiological Research, 42nd Annual Meeting, Washington, DC. 2002.
93. Osborne CA, O'Connor BJ, Lewis A, Kanabar V, Gardner WN. Hyperventilation and asymptomatic chronic asthma. *Thorax* 2000;55:1016–22.
94. O'Cain CF, Hensley MJ, McFadden ER Jr, Ingram RH Jr. Pattern and mechanism of airway response to hypocapnia in normal subjects. *Journal of Applied Physiology* 1979;47:8–12.
95. van den Elshout FJ, van Herwaarden CL, Folgering HT. Effects of hypercapnia and hypocapnia on respiratory resistance in normal and asthmatic subjects. *Thorax* 1991;46:28–32.
96. Buteyko KP, Odintsova MP, Nasonkina NS. The ventilation test in patients with bronchial asthma. *Vrachebnoe Delo* 1968;4:33–6 [article in Russian].
97. Kassabian J, Miller KD, Laviates MH. Respiratory center output and ventilatory timing in patients with acute airway (asthma) and alveolar (pneumonia) disease. *Chest* 1982;81:536–43.
98. Meuret AE, Ritz T, Wilhelm FH, Roth WT. Targeting overbreathing in asthma by self-modifications of pCO<sub>2</sub> levels. Paper submitted to the Society for Psychophysiological Research, 42nd Annual Meeting, Washington, DC. 2002.
99. Hypoxemia and hypocapnia in asthma. *New England Journal of Medicine* 1968;278:1068.
100. Domino KB, Lu Y, Eisenstein BL, Hlastala MP. Hypocapnia worsens arterial blood oxygenation and increases V<sub>a</sub>/Q heterogeneity in canine pulmonary edema. *Anesthesiology* 1993;78:91–9.
101. Budmiger H, Kyd K, Scherrer M. The bronchospasmolytics salbutamol, fenoterol, terbutaline and reproterol. Their effects and side effects in asthmatics after inhalation with an electric nebulizer. *Schweizerische Medizinische Wochenschrift* 1978;108:1190–7 [article in German].
102. Beckett PA, Howarth PH. Pharmacotherapy and airway remodelling in asthma? *Thorax* 2003;58:163–74.